Glenn Omanio

Glenn Omanio has extensive work experience in the pharmaceutical industry. Glenn currently holds the position of Head, US Marketing at Bavarian Nordic since October 2022. Prior to their current role, they worked at Takeda as the Director of Reimbursement and Access Marketing - Gastroenterology from January 2020 to September 2022. Before that, they served as the Director of US Marketing - Prescription Digital Therapeutics at Sandoz from July 2018 to January 2020. Glenn also has experience working as the Director of US Marketing - Influenza Vaccines at Seqirus from March 2016 to July 2018 and as the Director of US and Global Marketing - Influenza Vaccines at Novartis from March 2014 to February 2016. Prior to their roles at Novartis, they held positions such as Associate Director of US Marketing - Rabies and Japanese Encephalitis Vaccines from September 2012 to February 2014 and Manager of US Marketing - Meningococcal Vaccine from May 2010 to August 2012. Before entering the pharmaceutical industry, Glenn worked as a Staff Reporter at Kyodo News International, Inc from April 2003 to February 2008.

Glenn Omanio is currently pursuing an International Masters for Health Leadership degree at McGill University from 2021 to 2023. Prior to this, they attended The London School of Economics and Political Science (LSE) where they studied Health Economics, Management, and Policy. Additionally, they hold a Master of Business Administration (MBA) degree from Hult International Business School. In terms of undergraduate education, Glenn obtained a Bachelor of Arts (BA) degree in Journalism from the University of the Philippines Diliman. In terms of additional certifications, they completed a Managerial Finance program at The London School of Economics and Political Science (LSE) in May 2020. Furthermore, they have obtained a certification in Health Care Economics from Harvard University.